Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Biohaven Pharmaceutical Holding Co Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, neuroscience, and oncology. The company’s clinical pipeline includes multiple programs across different stages of development. Its late-stage candidates include BHV-8000 for Parkinson’s disease and Opakalim for focal epilepsy, both in Phase 3 trials. Additional programs in Phase 2 include BHV-1300 for Graves’ disease and rheumatoid arthritis, BHV-1400 for IgA nephropathy, BHV-2100 for pain disorders, BHV-2000 for obesity, BHV-1510 for advanced or metastatic epithelial tumors, and BHV-1530 for urothelial cancer and other tumors. Biohaven is also advancing early-stage and preclinical programs such as BHV-1600, BHV-1310, BHV-1320, BHV-1450, BHV-1420, BHV-1440, BHV-6500, BHV-1490, BHV-8100, and BHV-1955 across a range of therapeutic areas. Formerly known as Biohaven Research Ltd., the company adopted its current name in September 2022 and is headquartered in New Haven, Connecticut.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-BHVN
|
$13.37
|
-12.8% Downside
|
Fair
|
$22.75
|
48.4% Upside
|
Undervalued
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 3, 2026
|
-3.6x
|
17.9x
|
—
|
2.237 B
|
2.251 B
|
11.3%
|
82.2%
|
-6.6
|
—
|
91.8%
|
